ArticleScience translational medicine2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
Open access · hybridAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
287citing papers in PubMed, 2 pooled it
29.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
287 citing papers in PubMed, 2 syntheses or guidelines pooled it, 489 citations in OpenAlex.
- Predicting the presence of infectious virus from PCR data: A meta-analysis of SARS-CoV-2 in non-human primates.PLoS pathogens · 2024Pooled it
- The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.Journal of medical virology · 2022Pooled it
- Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.Pharmacology research & perspectives · 2023Trial
- A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.Nature communications · 2022Trial
- The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.Science translational medicine · 2022Trial
- Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.Journal of translational medicine · 2022Trial
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.Annals of internal medicine · 2022Trial
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Article
- Mass spectrometry-based mapping of conformational epitopes on SARS-CoV-2 antigens targeted by monoclonal antibodies.International journal of biological macromolecules · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- Variant-specific spike conformational dynamics shape memory B cell selection during recall.bioRxiv : the preprint server for biology · 2026Article
- Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- A High-Throughput Platform for Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution.bioRxiv : the preprint server for biology · 2026Article
- Selection of Functional Glycoforms in Anti-SARS-CoV-2 Human IgG1 Monoclonal Antibodies by FcγRIIIa Affinity Chromatography and Mass Spectrometry.Journal of medicinal chemistry · 2026Article
- Observation of redistribution for local conformational dynamics in cross-reactive antibody design.Journal of biochemistry · 2026Article
- Cattle antibodies identify a cross-serotype broadly neutralising foot-and-mouth disease virus epitope.NPJ vaccines · 2026Article
227 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
57 authors at 8 institutions in 2 countries.
Bryan E JonesLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA. jones_bryan_edward@lilly.com ester.falconer@abcellera.com.ORCID 0000-0003-4764-6290
Patricia L Brown-AugsburgerEli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0000-0002-6444-4749
Kizzmekia S CorbettVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-2641-4688
Kathryn WestendorfAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0002-7354-9470
Julian DaviesLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.ORCID 0000-0002-1715-3463
Thomas P CujecLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.ORCID 0000-0002-6582-7848
Christopher M WiethoffEli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0000-0001-9102-7492
Jamie L BlackbourneEli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0000-0003-4323-597X
Beverly A HeinzEli Lilly and Company, Indianapolis, IN 46225, USA.
Denisa FosterLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Richard E HiggsEli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0000-0003-0162-4109
Deepa BalasubramaniamLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.ORCID 0000-0001-7289-0178
Lingshu WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yi ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8228-2560
Eun Sung YangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3161-1624
Roza BidshahriAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0002-6940-7154
Lucas KraftAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Yuri HwangAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0002-5560-2696
Stefanie ŽentelisAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Kevin R JepsonAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0001-9349-9653
Rodrigo GoyaAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Maia A SmithAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
David W CollinsAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0001-9243-7821
Samuel J HinshawAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0002-3322-3492
Sean A TychoAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Davide PellacaniAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Ping XiangAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0003-1980-1513
Krithika MuthuramanAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Solmaz SobhanifarAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Marissa H PiperLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Franz J TrianaLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Jorg HendleLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.ORCID 0000-0001-8857-0216
Anna PustilnikLilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.ORCID 0000-0002-3668-4016
Andrew C AdamsEli Lilly and Company, Indianapolis, IN 46225, USA.
Shawn J BerensEli Lilly and Company, Indianapolis, IN 46225, USA.
Ralph S BaricUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-6827-8701
David R MartinezUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Robert W CrossGalveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-7718-1522
Thomas W GeisbertGalveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-0858-1877
Viktoriya BorisevichGalveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Olubukola AbionaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-2745-1691
Hayley M BelliDepartment of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-0816-6844
Maren de VriesDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-1059-8344
Adil MohamedDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-0080-2727
Meike DittmannDepartment of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-1741-7916
Marie I SamanovicNYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-6987-2232
Mark J MulliganNYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Jory A GoldsmithDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Ching-Lin HsiehDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-3665-5717
Nicole V JohnsonDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0003-4351-125X
Daniel WrappDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-0538-9647
Jason S McLellanDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0003-3991-542X
Bryan C BarnhartAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.ORCID 0000-0002-5640-1677
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-8112-0853
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5293-4695
Carl L HansenAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
Ester FalconerAbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada. jones_bryan_edward@lilly.com ester.falconer@abcellera.com.ORCID 0000-0003-1486-5251
AbCellera (Canada) · CAEli Lilly (United States) · USNational Institutes of Health · USThe University of Texas at Austin · USNew York University · USThe University of Texas Medical Branch at Galveston · USNYU Langone Health · USUniversity of North Carolina at Chapel Hill · US
Funding
Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8MEstablishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) - DMID 21-0012UM1AI148574 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Angelica Cifuentes Kottkamp, Anoma Nellore · 2020 to 2026
$23.9MALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)U01AI047996 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2000 to 2006
$8.4MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MELF1 - Molecular mechanisms of a novel transcription factor with broad antiviral activityR01AI143639 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEISER, JEFFREY NEAL · 2019 to 2023
$2.5MSERPINs as a novel family of innate antiviral molecules - Resubmission - 1R21AI139374 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DITTMANN, MEIKE · 2019 to 2020
$466kDefining viral and immune mechanisms of Dengue virus serotype 2 immune evasionF32AI152296 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARTINEZ, DAVID R. · 2020 to 2020
$41kNIAID NIH HHS F32 AI152296NIAID NIH HHS R01 AI143639NIAID NIH HHS R01 AI157155NIAID NIH HHS R21 AI139374NIAID NIH HHS T32 AI007151NIAID NIH HHS U01 AI047996NIAID NIH HHS UC7 AI094660NIAID NIH HHS UM1 AI148574NIH HHS AI157155NIH HHS UM1AI48574Wellcome Trust
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less responsive to vaccination. Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19). Biochemical, structural, and functional characterization of LY-CoV555 revealed high-affinity binding to the receptor-binding domain, angiotensin-converting enzyme 2 binding inhibition, and potent neutralizing activity. A pharmacokinetic study of LY-CoV555 conducted in cynomolgus monkeys demonstrated a mean half-life of 13 days and a clearance of 0.22 ml hour
Indexed as
Antibodies, NeutralizingCOVID-19AnimalsAntibodies, ViralMacaca mulattaSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.